Milana A. Losich

Milana A. Losich

Auto-generated profile, based on publicly available information

Milana A. Losich

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, Ministry of Health of the Russian Federation, Moscow

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2023 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
OZO. N. Zaykova
O. N. Zaykova
MLM. A. Losich
M. A. Losich
ERE. V. Rusakova
E. V. Rusakova
OVO. A. Verkhovsky
O. A. Verkhovsky
ASA. A. Shabeykin
A. A. Shabeykin
Tatiana Vladimirovna GrebennikovaTatiana Vladimirovna Grebennikova
Tatiana Vladimirovna Grebennikova
Relevance. Rabies, hydrophobia is an acute viral zoonotic neuroinfection with 100% mortality in the case of clinical signs in humans or animals. The main biological reservoirs and distributors of the rabies pathogen (Lyssa virus, Rhabdo viridae) on the territory of the Russian Federation (RF) are wild predators of the canine family responsible for the circulation of the classic rabies virus (Rabies virus). Also on the territory of the RF and the countries of Eastern Europe, Asia Minor and Central Asia, the circulation of 6 more species of viruses of the genus Lyssavirus, with biological reservation in bat populations, has been established. Despite the existing genetic and environmental differences, all types of lyssaviruses registered in the territory of the RF pose a threat to humans and animals. Due to the growing processes of interpenetration of the anthropogenic environment and wildlife, in recent years, rabies has been increasingly registered in domestic carnivores, which significantly increases epidemiological risks. Aim. A retrospective comparative analysis of data on the incidence of rabies in humans and animals in the RF and on the territory of some regions of Eurasia adjacent to the RF for the period from 2013 to 2021 to characterize the current manifestations of the epidemic (epizootic) process of rabies. Materials and methods. The materials for the study were data from epidemiological surveillance of rabies in the RF and data from veterinary statistics for 2013–2021. Conventional methods and computer programs were used for the analysis: Microsoft Office Excel analysis package, as well as an online statistical calculator. The level of reliability of the data obtained was evaluated using the Pearson consensus criterion χ2, with a reliability level of p = 0.05 and p = 0.01. Results. It is shown that, on average, 2312.33 ± 752.24 cases of rabies in animals were registered on the territory of the RF for the period 2013–2021. With the observed trend towards a gradual decrease in the annual incidence of rabies among animals, the share of dogs and cats in the epizootic process has increased by 7.,4 and 3,8%, respectively, over the past 2 years. At the same time, an increase in the incidence of rabies in humans by 4,33 times was recorded when comparing indicators with the previous period 2018-2019. Russia in total for 2013-2021 ranks first in the number of officially registered cases of rabies in humans (63%) among the countries of Europe, the Caucasus, Transcaucasia and Central Asia. The European part of the RF accounts for 41,7–44,3% of cases of rabies among domestic and farm animals and 46,7% among wild animals compared to these regions. The recorded trend towards a decrease in the number of cases of rabies in animals can be explained by long-term oral vaccination of wild carnivores. But the decrease in the number of natural foci of the disease did not provoke a proportional decrease in the incidence of rabies in domestic animals. As a result, the proportion of dogs and cats in the morbidity structure has significantly increased, which, given their proximity to humans, ensures the maintenance of a high level of epidemiological risk. In the pan-European incidence of rabies, the RF is in second place after the countries of Eastern and Southern Europe. All reported cases of rabies in the RF are caused by the natural circulation of the «classic» rabies virus. In recent years, no lyssaviruses have been detected in bat populations on the territory of the RF, which contrasts with the high incidence of lyssaviruses in other European countries. The RF shares land borders with the countries of Europe, the Caucasus, Transcaucasia and Central Asia, at the same time, the territory of the RF has extensive areas of Eptesicus serotinus and Myotis daubentonii, which are biological reservoirs for EBLV-1, EBLV-2. Based on the above, the risk of the permanent presence of lyssaviruses in bat populations in the territory of the RF is very high and requires monitoring on a regular basis. Conclusion. The analysis of epidemiological and epizootological risks shows the need to adjust the ongoing preventive anti-rabies measures. It is necessary to intensify the campaign of anti-rabies vaccination of domestic carnivores, reduce the number of neglected animals, expand the program for oral vaccination of wild carnivores, monitor the prevalence of lyssaviruses in bat populations in the territory of the RF.

1 January 2019 in Биоорганическая химия
Verified
Journal Article
Closed access
ЕИЕ. Н. Ильина
Е. Н. Ильина
ОСО. Н. Солопова
О. Н. Солопова
ДБД. С. Балабашин
Д. С. Балабашин
МЛМ. В. Ларина
М. В. Ларина
ТАТ. К. Алиев
Т. К. Алиев
МКМ. П. Кирпичников
М. П. Кирпичников

20 February 2020 in Problems of Virology
Verified
Journal Article
Open access
PDF file
OZO. N. Zaykova
O. N. Zaykova
Tatiana Vladimirovna GrebennikovaTatiana Vladimirovna Grebennikova
Tatiana Vladimirovna Grebennikova
MLM. A. Losich
M. A. Losich
AEA. L. Elakov
A. L. Elakov
AGA. M. Gulyukin
A. M. Gulyukin
AMArtem Metlin
Artem Metlin
Introduction. Rabies caused by the neurotropic virus of the genus Lyssavirus, Rhabdoviridae family, which infects all warm-blooded vertebrates including human beings. The homology level of the amino acid sequences for Lyssaviruses nucleoprotein reaches 78–93%.Aim – study the genetic diversity and molecular epidemiology of Lyssaviruses circulated in the Russian Federation in 1985–2016.Material and methods. 54 isolates of rabies virus isolated from animals, and 2 isolates from humans, 4 vaccine strains of rabies virus: RV-97, ERA, Shchelkovo 51, ERAG333 used in phylogenetic study. Phylogenetic analysis was performed using Genbank data on genome fragments of 73 rabies virus isolates and 9 EBLV-1 isolates. DNASTAR V.3.12, Bio Edit 7.0.4.1 and MEGA v.10.0.5, Primer Premier 5 programs have been used.Results. Comparative molecular genetic analysis of genomes fragments of 130 Lissaviruses, isolated on the territory of the RF, Ukraine in 1985-2016, vaccine strains of rabies virus, showed their distribution by geographical feature. Comparison of the nucleoprotein fragments of the rabies virus isolates with vaccine strains revealed 4 marker mutations: V56I (Eurasian group), L/V95W (Central group), D101N/S/T, and N/G106D. Phylogenetic analysis of the isolate «Juli», isolated from a human bitten by a bat proved his belonging to the European Bat lyssavirus-1a.Discussion. Study of the molecular epidemiology of rabies within the Russian Federation allows for the genotyping of the viruses and helps to study the hidden mechanisms of rabies infection in animal and human populations, and to characterize vaccine strains, including during oral vaccination.Conclusion. Further study of the molecular epidemiology of rabies within the Russian Federation and the countries bordering it is important.

1 January 2020 in Immunologiya
Verified
Journal Article
Open access
FFFederal Research Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation
Federal Research Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation
MSMaxim Shmarov
Maxim Shmarov
IUI.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University)
I.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University)
ESE.S. Sedova
E.S. Sedova
ANA.E. Nikonova
A.E. Nikonova
AGA.L. Gintsburg
A.L. Gintsburg

12 May 2025 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
Tatiana Vladimirovna GrebennikovaTatiana Vladimirovna Grebennikova
Tatiana Vladimirovna Grebennikova
OZOlga N. Zaykova
Olga N. Zaykova
APAlexey A. Plotnikov
Alexey A. Plotnikov
LKLyudmila V. Kostina
Lyudmila V. Kostina
YCYana Chernoryzh
Yana Chernoryzh
ЦВЦибезов Валерий Владимирович
Цибезов Валерий Владимирович
Introduction. One of the more promising developments in preventing the spread of infections, including COVID-19, is the production of vaccines based on virus-like particles (VLP). Currently, in the National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russia has developed a VLP-based vaccine against COVID-19. The aim of this study is to evaluate the tolerability, safety and immunogenicity of a new vaccine for the prevention of COVID–19 based on VLP compared with placebo for 21 days after two intramuscular injections in phase I clinical trials. Materials and methods. A double-blind, placebo-controlled study of the tolerability, safety and immunogenicity of a vaccine for the prevention of COVID-19 based on VLP was conducted with a dose of the drug containing 40 and 80 micrograms of antigen, the placebo being 0.9% NaCl. The presence or absence of adverse events (AEs) after vaccination was noted in 180 volunteers aged 18 to 55 years; clinical and biochemical blood parameters, the intensity of humoral and cellular immunity before and after vaccination were assessed using enzyme immunoassay, neutralization reactions, lymphocyte blast transformation reactions and flow cytometry. Results. An analysis of the tolerability and safety of the new COVID-19 VLP-vaccine showed that most adverse events were registered within the first 10 days after vaccination, mainly after the first vaccination. In the period from 11 to 21 days after vaccination, AEs were observed in isolated cases. No deaths, serious or other AEs have been reported. The administration of the studied vaccine to the volunteers had no negative effect on the basic vital signs. A comparative analysis of immunogenicity indicators in volunteers showed that the administration of a vaccine with both an antigen content of 40 µg and an antigen content of 80 µg leads to a pronounced and significant increase in the level of specific immunoglobulins, virus neutralizing antibodies and activation of a cell-mediated immune response. As part of the phase I clinical trials, a dose of 80 µg was selected as optimal. Conclusion. It has been shown that a new vaccine for the prevention of COVID-19 based on VLP with an antigen content of 40 and 80 µg when administered intramuscularly to volunteers does not cause serious adverse events and induces a tense humoral and cellular immune response.